Lv3
260 积分 2024-12-25 加入
Plasma ctDNA as a Treatment Response Biomarker in Metastatic Cancers: Evaluation by the RECIST Working Group
1个月前
已完结
ESR1 mutations in HR+/HER2-metastatic breast cancer: Enhancing the accuracy of ctDNA testing
1个月前
已完结
Circulating tumor DNA as a biomarker in early phase clinical trials
1个月前
已完结
A Multicenter Study of Hereditary Transthyretin Amyloidosis in China
1个月前
已完结
Precision Oncology: 2025 in Review
2个月前
已完结
Expression of cluster of differentiation 47 (CD47) and signal regulatory protein alpha (SIRPα) as prognostic biomarkers and potentially therapeutic targets in esophageal squamous cell carcinoma
2个月前
已完结
Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy
3个月前
已完结
Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial
3个月前
已完结
Adjuvant nivolumab in muscle-invasive urothelial carcinoma: exploratory biomarker analysis of the randomized phase 3 CheckMate 274 trial
3个月前
已完结
ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer
3个月前
已完结
皖公网安备34019202002308
